Effects of dopamine agonists in tardive dyskinesia

R. C. Smith, C. A. Tamminga, J. Haraszti, G. N. Pandey, J. M. Davis

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

The authors used a combined behavioral and neuroendocrinological strategy to investigate the relevance of abnormalities in the brain dopaminergic systems to the pathophysiology of tardive dyskinesia by assessing the effects of apomorphine, a directly acting dopamine agonist, and d-amphetamine, an indirectly acting dopamine agonist, in patients with tardive dyskinesia. Administration of i.v. d-amphetamine increased dyskinetic movements in most patients with tardive dyskinesia, a finding consistent with the dopaminergic hypothesis. Contrary to predictions based on animal models, apomorphine did not increase dyskinetic movements in these patients but instead substantially reduced dyskinesia in some patients. Patients with tardive dyskinesia did not have a greater drop in serum prolactin or a greater rise in serum growth hormone after apomorphine than normal or chronic schizophrenic subjects without tardive dyskinesia.

Original languageEnglish (US)
Pages (from-to)763-768
Number of pages6
JournalAmerican Journal of Psychiatry
Volume134
Issue number7
StatePublished - 1977

Fingerprint

Dopamine Agonists
Apomorphine
Dextroamphetamine
Dyskinesias
Serum
Prolactin
Growth Hormone
Animal Models
Tardive Dyskinesia
Brain

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Smith, R. C., Tamminga, C. A., Haraszti, J., Pandey, G. N., & Davis, J. M. (1977). Effects of dopamine agonists in tardive dyskinesia. American Journal of Psychiatry, 134(7), 763-768.

Effects of dopamine agonists in tardive dyskinesia. / Smith, R. C.; Tamminga, C. A.; Haraszti, J.; Pandey, G. N.; Davis, J. M.

In: American Journal of Psychiatry, Vol. 134, No. 7, 1977, p. 763-768.

Research output: Contribution to journalArticle

Smith, RC, Tamminga, CA, Haraszti, J, Pandey, GN & Davis, JM 1977, 'Effects of dopamine agonists in tardive dyskinesia', American Journal of Psychiatry, vol. 134, no. 7, pp. 763-768.
Smith RC, Tamminga CA, Haraszti J, Pandey GN, Davis JM. Effects of dopamine agonists in tardive dyskinesia. American Journal of Psychiatry. 1977;134(7):763-768.
Smith, R. C. ; Tamminga, C. A. ; Haraszti, J. ; Pandey, G. N. ; Davis, J. M. / Effects of dopamine agonists in tardive dyskinesia. In: American Journal of Psychiatry. 1977 ; Vol. 134, No. 7. pp. 763-768.
@article{b1d6b110651041b1a23aba95551a6324,
title = "Effects of dopamine agonists in tardive dyskinesia",
abstract = "The authors used a combined behavioral and neuroendocrinological strategy to investigate the relevance of abnormalities in the brain dopaminergic systems to the pathophysiology of tardive dyskinesia by assessing the effects of apomorphine, a directly acting dopamine agonist, and d-amphetamine, an indirectly acting dopamine agonist, in patients with tardive dyskinesia. Administration of i.v. d-amphetamine increased dyskinetic movements in most patients with tardive dyskinesia, a finding consistent with the dopaminergic hypothesis. Contrary to predictions based on animal models, apomorphine did not increase dyskinetic movements in these patients but instead substantially reduced dyskinesia in some patients. Patients with tardive dyskinesia did not have a greater drop in serum prolactin or a greater rise in serum growth hormone after apomorphine than normal or chronic schizophrenic subjects without tardive dyskinesia.",
author = "Smith, {R. C.} and Tamminga, {C. A.} and J. Haraszti and Pandey, {G. N.} and Davis, {J. M.}",
year = "1977",
language = "English (US)",
volume = "134",
pages = "763--768",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "7",

}

TY - JOUR

T1 - Effects of dopamine agonists in tardive dyskinesia

AU - Smith, R. C.

AU - Tamminga, C. A.

AU - Haraszti, J.

AU - Pandey, G. N.

AU - Davis, J. M.

PY - 1977

Y1 - 1977

N2 - The authors used a combined behavioral and neuroendocrinological strategy to investigate the relevance of abnormalities in the brain dopaminergic systems to the pathophysiology of tardive dyskinesia by assessing the effects of apomorphine, a directly acting dopamine agonist, and d-amphetamine, an indirectly acting dopamine agonist, in patients with tardive dyskinesia. Administration of i.v. d-amphetamine increased dyskinetic movements in most patients with tardive dyskinesia, a finding consistent with the dopaminergic hypothesis. Contrary to predictions based on animal models, apomorphine did not increase dyskinetic movements in these patients but instead substantially reduced dyskinesia in some patients. Patients with tardive dyskinesia did not have a greater drop in serum prolactin or a greater rise in serum growth hormone after apomorphine than normal or chronic schizophrenic subjects without tardive dyskinesia.

AB - The authors used a combined behavioral and neuroendocrinological strategy to investigate the relevance of abnormalities in the brain dopaminergic systems to the pathophysiology of tardive dyskinesia by assessing the effects of apomorphine, a directly acting dopamine agonist, and d-amphetamine, an indirectly acting dopamine agonist, in patients with tardive dyskinesia. Administration of i.v. d-amphetamine increased dyskinetic movements in most patients with tardive dyskinesia, a finding consistent with the dopaminergic hypothesis. Contrary to predictions based on animal models, apomorphine did not increase dyskinetic movements in these patients but instead substantially reduced dyskinesia in some patients. Patients with tardive dyskinesia did not have a greater drop in serum prolactin or a greater rise in serum growth hormone after apomorphine than normal or chronic schizophrenic subjects without tardive dyskinesia.

UR - http://www.scopus.com/inward/record.url?scp=0017646434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017646434&partnerID=8YFLogxK

M3 - Article

C2 - 869053

AN - SCOPUS:0017646434

VL - 134

SP - 763

EP - 768

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 7

ER -